ロード中...
Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels
We identified previously in vitro LRP4 (low-density lipoprotein receptor-related protein 4) as a facilitator of the WNT (Wingless-type) antagonist sclerostin and found mutations disrupting this function to be associated with high bone mass in humans similar to patients lacking sclerostin. To further...
保存先:
| 出版年: | Proc Natl Acad Sci U S A |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
National Academy of Sciences
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4260537/ https://ncbi.nlm.nih.gov/pubmed/25404300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1413828111 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|